Description

IYPTNGYTR acetate, a deamidation-sensitive signature peptide, is a deamidation product of Trastuzumab. IYPTNGYTR acetate can be used to monitor in vivo Trastuzumab metabolism[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C51H77N13O17—-[1]Bults P, et, al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016 Feb 2;88(3):1871-7.—-1144.23–99.41–CC(O)=O.O=C(N(CCC1)[C@@H]1C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(N)=O)C(NCC(N[C@H](C(N[C@@H]([C@H](O)C)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)CC(C=C2)=CC=C2O)=O)=O)=O)=O)[C@@H](NC([C@@H](N)[C@@H](C)CC)=O)CC(C=C3)=CC=C3O–Others–H2O : 125 mg/mL (ultrasonic)–Drug Metabolite—-Metabolic Enzyme/Protease–Peptides